Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizu...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$122.82

 3.2 (2.54%)

03/26/19  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics - March 6, 2019
Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discove... Read More
BeiGene to Present at Upcoming Investor Conferences - March 4, 2019
CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a ... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts